Phio Pharmaceuticals Corp.

NASDAQ (USD): Phio Pharmaceuticals Corp. (PHIO)

Last Price

1.81

Today's Change

+0.02 (1.11%)

Day's Change

1.79 - 1.88

Trading Volume

255,542

Overview

Market Cap

8 Million

Shares Outstanding

4 Million

Avg Volume

6,560,208

Avg Price (50 Days)

2.36

Avg Price (200 Days)

3.77

PE Ratio

-0.19

EPS

-9.75

Earnings Announcement

31-Mar-2025

Previous Close

1.79

Open

1.83

Day's Range

1.79 - 1.88

Year Range

1.53 - 10.35

Trading Volume

257,846

Price Change Highlight

1 Day Change

1.12%

5 Day Change

-5.24%

1 Month Change

-34.66%

3 Month Change

-18.10%

6 Month Change

-39.26%

Ytd Change

-4.74%

1 Year Change

-73.54%

3 Year Change

-98.09%

5 Year Change

-99.48%

10 Year Change

-100.00%

Max Change

-99.43%

News and Blogs

No result.

Company Profile

Sector: Healthcare - Healthcare

Industry: Biotechnology

Description:

Phio Pharmaceuticals Corp. develops immuno-oncology therapeutics in the United States. It offers INTASYL therapeutic platform focuses on targeting tumor and immune cells by regulating genes of the immune system. The company develops PH-762 that activates immune cells to recognize and kill cancer cells by reducing the expression of the checkpoint protein PD-1 for immunotherapy in adoptive cell transfer (ACT); PH-894 that silences the epigenetic protein BRD4, which is an intracellular regulator of gene expression for use in ACT; and PH-804 that targets the suppressive immune receptor TIGIT, which is a checkpoint protein present on T cells and natural killer cells for use in ACT. It has collaborations with AgonOx Inc. on clinical development of novel T cell-based cancer immunotherapies. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is headquartered in Marlborough, Massachusetts.

Discussions
Be the first to like this. Showing 0 of 0 comments

Post a Comment